Raymond Portis, MD
Pulmonary Disease · Jackson, MSNPI 1437312915
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (45.2%), food and beverage and education — rather than concentrated in one kind of arrangement. 40 manufacturers reported payments, led by Mallinckrodt Enterprises LLC at 42.5% of the total. Reporting peaked in 2019 at $18,786 and has fallen 91.5% since, to $1,595 in 2025. Among pulmonary disease clinicians in MS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 645 payments — averaging $59.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Enterprises LLC$16K
- Intuitive Surgical$10K
- GSK$4K
- Mallinckrodt Hospital Products Inc.$2K
- AstraZeneca$1K
- Actelion Pharmaceuticals US, Inc.$956
- plus $4K from 34 others
What the payments were for
- Speaking & faculty fees$17,44545%
- Travel & lodging$8302%
- Food & beverage$11,23229%
- Education$9,10924%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Enterprises LLC | 7 | $16,393 |
| Intuitive Surgical | 11 | $9,848 |
| GSK | 230 | $3,508 |
| Mallinckrodt Hospital Products Inc. | 27 | $1,986 |
| AstraZeneca | 71 | $1,455 |
| Actelion Pharmaceuticals US, Inc. | 38 | $956 |
| Insmed, Inc. | 31 | $563 |
| Boehringer Ingelheim | 33 | $505 |
| United Therapeutics Corporation | 15 | $318 |
| Genentech USA, Inc. | 16 | $264 |
| Sunovion Pharmaceuticals Inc. | 13 | $254 |
| Sanofi | 12 | $236 |
| Johnson & Johnson | 14 | $224 |
| Mylan Specialty L.p. | 13 | $218 |
| Grifols USA, LLC | 10 | $171 |
| Regeneron Healthcare Solutions, Inc. | 6 | $161 |
| Jazz Pharmaceuticals Inc. | 6 | $152 |
| Merck | 9 | $152 |
| Pfizer | 8 | $141 |
| AbbVie | 14 | $132 |
| Gilead | 6 | $103 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $97 |
| Bayer | 5 | $77 |
| ANI Pharmaceuticals, Inc. | 4 | $73 |
| Baxter Healthcare | 4 | $72 |
| E.r. Squibb & Sons, L.L.C. | 5 | $70 |
| Inari Medical, Inc. | 4 | $64 |
| Electromed, Inc. | 8 | $62 |
| Novartis | 4 | $57 |
| Philips North America LLC | 2 | $50 |
| Amgen | 2 | $43 |
| Covidien LP | 2 | $43 |
| Pulmonx Corporation | 2 | $37 |
| Axsome Therapeutics, Inc. | 1 | $35 |
| Verona Pharma, Inc. | 1 | $24 |
| Ambu Inc. | 1 | $18 |
| Viatris Specialty LLC | 1 | $16 |
| Portola Pharmaceuticals, LLC | 1 | $15 |
| Mayne Pharma Commercial LLC | 1 | $13 |
| Circassia Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$38,616 in reported general payments places this provider in the 90th percentile of 101 pulmonary disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 25 | $322,371 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 388 | $318,822 |
| Dupixent PenDupilumab | 58 | $234,516 |
| OpsumitMacitentan | 12 | $149,429 |
| TezspireTezepelumab-Ekko | 24 | $108,858 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 135 | $97,647 |
| Ambrisentan | 29 | $82,423 |
| Breo ElliptaFluticasone/Vilanterol | 102 | $51,056 |
| Spiriva RespimatTiotropium Bromide | 76 | $39,410 |
| EliquisApixaban | 53 | $36,547 |
| SymbicortBudesonide/Formoterol Fumarate | 62 | $17,799 |
| Tadalafil | 17 | $16,836 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 25 | $14,133 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 341 | $13,230 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 22 | $9,975 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $3,508 | $384,855523 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $505 | $375,914126 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $1,455 | $224,304221 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $956 | $149,42912 claims |
| PfizerEliquis | $141 | $36,54753 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 101 pulmonary disease providers in Mississippi.
Other pulmonary disease in Jackson
- Demondes HaynesJackson$809K
- Michal SenitkoJackson$185K
- Andrew WilhelmJackson$51K
- George AbrahamJackson$23K
- Maria RappaiJackson$20K
- Arash SamarghandiJackson$19K
- Kimberly DobbsJackson$14K
- Rajesh PatelJackson$13K
- Charles EvansJackson$12K
- Meredith SloanJackson$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.